Angela Ma Bengtson

Angela Ma Bengtson

Auto-generated profile, based on publicly available information

Angela Ma Bengtson

Department of Epidemiology, Emory University, Atlanta, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
BPBrian W. Pence
Brian W. Pence
JMJon C. Mills
Jon C. Mills
ABAngela M. Bengtson
Angela M. Bengtson
BGBradley N. Gaynes
Bradley N. Gaynes
TBTiffany L. Breger
Tiffany L. Breger
MMMichael J. Mugavero
Michael J. Mugavero
Depression is one of the most common comorbidities affecting adults living with HIV, with prevalence estimates ranging from 20% to 40%.1-7 In addition to being a serious clinical concern, depression complicates the management of HIV: it has been linked to low adherence to antiretroviral therapy (ART),8 poor attendance at HIV primary care appointments,9 ART failure,10 accelerated clinical progression of HIV,11,12 and higher mortality rates.13-24

1 December 2019 in Journal of Affective Disorders
Verified
Journal Article
Open access
JPJennifer Pellowski
Jennifer Pellowski
ABAngela M. Bengtson
Angela M. Bengtson
WBWhitney Barnett
Whitney Barnett
KDKira DiClemente-Bosco
Kira DiClemente-Bosco
NKNastassja Koen
Nastassja Koen
DSDan J. Stein
Dan J. Stein
Perinatal depression affects 21-50% of women in South Africa and poses significant health risks to mothers and children. Trajectories of depressive symptoms change over time and have not been well characterized during the perinatal period in low and middle-income countries. Data from women enrolled in a population-based birth cohort study in Paarl, South Africa with at least 3 depression measures from pregnancy through 18 months postpartum (N = 831) were analyzed. Depressive symptoms were measured continuously using the Edinburgh Postnatal Depression Scale (EPDS). Group-based trajectory models were used to estimate trajectories of depressive symptoms during the perinatal period and multinomial multivariable models to identify predictors of trajectory group membership. Five distinct trajectory patterns of depressive symptoms were identified: moderate levels of depressive symptoms during pregnancy but minimal postpartum (3.5%), minimal levels during pregnancy and increasing postpartum (3.7%), unstable levels peaking at 12 months postpartum (6.6%), mild levels with slight decrease postpartum (82.9%), and severe levels during pregnancy and postpartum (3.1%). Membership in the chronic severe symptom group was associated with stressful life events, sexual intimate partner violence and tobacco use. Modeling limitations prevented determining how changes in psychosocial predictors over time may influence depressive symptom trajectories. Mild to severe depressive symptoms during pregnancy/postpartum were common among this South African cohort. Interventions to treat women with severe chronic depressive symptoms with co-occurring psychosocial issues are urgently needed.

21 April 2023 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
ABAngela M. Bengtson
Angela M. Bengtson
TFTeresa R. Filipowicz
Teresa R. Filipowicz
SMSteven Mphonda
Steven Mphonda
MUMichael Udedi
Michael Udedi
KKKazione Kulisewa
Kazione Kulisewa
BPBrian Wells Pence
Brian Wells Pence

13 July 2018 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
BPBrian W. Pence
Brian W. Pence
ABAngela M. Bengtson
Angela M. Bengtson
SBStephen Boswell
Stephen Boswell
KCKaterina A. Christopoulos
Katerina A. Christopoulos
HCHeidi M. Crane
Heidi M. Crane
MMMichael J. Mugavero
Michael J. Mugavero

11 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAngela M Bengtson
Angela M Bengtson
BPBrian W Pence
Brian W Pence
HCHeidi M Crane
Heidi M Crane
KCKaterina Christopoulos
Katerina Christopoulos
RFRob J Fredericksen
Rob J Fredericksen
MMMichael J Mugavero
Michael J Mugavero
To describe disparities along the depression treatment cascade, from indication for antidepressant treatment to effective treatment, in HIV-infected individuals by gender and race/ethnicity. The Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) cohort includes 31,000 HIV-infected adults in routine clinical care at 8 sites. Individuals were included in the analysis if they had a depressive symptoms measure within one month of establishing HIV care at a CNICS site. Depressive symptoms were measured using the validated Patient Health Questionnaire-9 (PHQ-9). Indication for antidepressant treatment was defined as PHQ-9 ≥ 10 or a current antidepressant prescription. Antidepressant treatment was defined as a current antidepressant prescription. Evidence-based antidepressant treatment was considered treatment changes based on a person’s most recent PHQ-9, in accordance with clinical guidelines. We calculated the cumulative probability of moving through the depression treatment cascade within 24 months of entering CNICS HIV care. We used multivariable Cox proportional hazards models to estimate associations between gender, race/ethnicity, and a range of depression outcomes. In our cohort of HIV-infected adults in routine care, 47% had an indication for antidepressant treatment. Significant drop-offs along the depression treatment cascade were seen for the entire study sample. However, important disparities existed. Women were more likely to have an indication for antidepressant treatment (HR 1.54; 95% CI 1.34, 1.78), receive antidepressant treatment (HR 2.03; 95% CI 1.53, 2.69) and receive evidence-based antidepressant treatment (HR 1.67; 95% CI 1.03, 2.74), even after accounting for race/ethnicity. Black non-Hispanics (HR 0.47, 95% CI 0.35, 0.65), Hispanics (HR 0.63, 95% CI 0.44, 0.89) and other race/ethnicities (HR 0.35, 95% CI 0.17, 0.73) were less likely to initiate antidepressant treatment, compared to white non-Hispanics. In our cohort of HIV-infected adults depressive symptoms were common. Important disparities in the prevalence of depressive symptoms and receipt of antidepressant treatment existed by gender and race/ethnicity.

8 August 2014 in AIDS Care
Verified
Journal Article
Closed access
ABAngela M. Bengtson
Angela M. Bengtson
BPBrian W. Pence
Brian W. Pence
JOJulie O'DOnnell
Julie O'DOnnell
NTNathan Thielman
Nathan Thielman
AHAmy Heine
Amy Heine
BGBradley Gaynes
Bradley Gaynes
Improving quality of life (QOL) for HIV-infected individuals is an important objective of HIV care, given the considerable physical and emotional burden associated with living with HIV. Although worse QOL has been associated with depression, no research has quantified the potential of improvement in depression to prospectively improve QOL among HIV-infected adults. We analyzed data from 115 HIV-infected adults with depression enrolled in a randomized controlled trial to evaluate the effectiveness of improved depression care on antiretroviral drug adherence. Improvement in depression, the exposure of interest, was defined as the relative change in depression at six months compared to baseline and categorized as full response (≥50% improvement), partial response (25–49% improvement), and no response (<25% improvement). Multivariable linear regression was used to investigate the relationship between improvement in depression and four continuous measures of QOL at six months: physical QOL, mental QOL, HIV symptoms, and fatigue intensity. In multivariable analyses, physical QOL was higher among partial responders (mean difference [MD] = 2.51, 95% CI: −1.51, 6.54) and full responders (MD = 3.68, 95% CI: −0.36, 7.72) compared to individuals who did not respond. Mental QOL was an average of 4.01 points higher (95% CI: −1.01, 9.03) among partial responders and 14.34 points higher (95% CI: 9.42, 19.25) among full responders. HIV symptoms were lower for partial responders (MD = −0.69; 95% CI: −1.69, 0.30) and full responders (MD = −1.51; 95% CI: −2.50, −0.53). Fatigue intensity was also lower for partial responders (MD = −0.94; 95% CI: −1.94, 0.07) and full responders (MD = −3.00; 95% CI: −3.98, −2.02). Among HIV-infected adults with depression, improving access to high-quality depression treatment may also improve important QOL outcomes.